anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a non-aerosol and one agent hair decolorant capable of foamingly discharging a liquid hair decolorant composition containing hydrogen peroxide and a foaming agent. SOLUTION: This hair decolorant contains <=6wt.% hydrogen peroxide, 0.1-5wt.% foaming agent and further 0.01-2wt.% silicone compound as effective ingredients. As the foaming agent, an amphoteric surfactant (e.g. a fatty acid amide propylbetain) is preferably used together with a cationic surfactant (e.g. chlorinated alkyltrimethylammmonium). The hair decolorant composition is filled as an inside solution in a foamer vessel having a means capable of mixing the inside solution and air and foamingly discharge the mixture. The vessel is not corroded with hydrogen peroxide. The inside pressure of the vessel does not increase excessively. The foam discharged from the hair decolorant has foam qualities adaptable to hair, is not sticky after applying to the hair and is capable of imparting good feeling to the hair.
The following adverse reactions have been identified during post-approval use of XIAFLEX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Acute Lower Back Pain Reactions

Reports of acute lower back pain reactions, sometimes accompanied by radiation of pain to the lower extremities, chest and arms, muscle spasms, chest pain, paresthesias and dyspnea, have been received involving patients treated with XIAFLEX for Peyronie’s disease. Some patients have also experienced temporary gait instability and an inability to ambulate for brief periods of time post injection. These events have occurred in close temporal proximity to XIAFLEX treatments. During retreatment injections with XIAFLEX, cases of recurrent acute lower back pain reactions have been reported. These events can be mild to severe in intensity. The events typically resolved within 15 minutes, but some lasted up to 30 minutes, and one event lasted 1.5 hours. The events typically did not require intervention, but some required observation and treatment with analgesics. The events typically resolved without sequelae, but in one event, pain improved but did not resolve at the time of final report.

Skin and Soft Tissue Necrosis Events 

Reports of localized skin and soft tissue necrosis, occurring as sequelae of penile hematoma, have been received in patients treated with XIAFLEX for Peyronie’s disease. Some of the cases required surgical intervention.

Syncope and Presyncope

Cases of syncope and presyncope have been reported in the postmarketing period in patients treated with XIAFLEX. Potential triggers for the syncopal events, including post-procedure pain, suggest a vasovagal mechanism. Most, but not all the cases, occurred in the immediate treatment period or within 1 to 2 days following injection. Bodily injuries, including concussion, head abrasion, and other accidental injuries, have been reported in association with the syncopal events.
Phenytoin sodium is related to the barbiturates in chemical structure, but has a five-membered ring. The chemical name is 5,5-diphenyl-2,4 imidazolidinedione, having the following structural formula:

Each 100 mg extended phenytoin sodium capsule USP contains 100 mg phenytoin sodium USP. Also contains confectioner’s sugar, hypromellose, magnesium oxide, magnesium stearate, microcrystalline cellulose, and talc. In addition, the empty hard gelatin capsule shells also contain gelatin, sodium lauryl sulphate, and titanium dioxide. The capsules are imprinted with edible ink containing black iron oxide, potassium hydroxide, propylene glycol and shellac. Product in vivoperformance is characterized by a slow and extended rate of absorption with peak blood concentrations expected in 4 to 12 hours as contrasted to Prompt Phenytoin Sodium Capsules, USP with a rapid rate of absorption with peak blood concentration expected in 1½ to 3 hours. 

Meets USP Dissolution Test 2.
Arm 1 will receive tailored surgery. If there are no cancer cells or the margin is negative in the local excision/biopsy during surgery, the operation will be terminated. And if the final pathology result is T2-4, or cancer cells and margin are positive in the frozen section during surgery, or the result of digital rectal examination and visual examination using anoretractor under general anesthesia is not suitable for local excision (visible and palpable tumor nodules), a total mesorectal excision will be performed.
Methods of and kits for determining the pharmacogenetic, pharmacokinetic and cellular basis of bisphosphonate-induced osteonecrosis of the jaw (BONJ) involve associating particular proteins and particular single nucleotide polymorphisms with a risk for developing BONJ after receiving bisphosphonate treatment. Methods and kits for identifying the genetic basis for a patient's predisposition to BONJ, and methods of identifying patients who are prone to develop BONJ following bisphosphonate administration provide for the development of a tool for physicians to prescribe treatment protocols for BONJ patients based on the patients' genomes (“personal/tailored medicine”). A haplotype tagging SNP approach was used to analyze candidate genes involved in bone absorption and destruction and to examine the influence of genetic variants on the susceptibility of BONJ. Bone biomarkers of BONJ were examined using molecular cell techniques. The methods described herein can be used to identify differences in how patients are genetically predisposed to BONJ as well as genetic differences amongst patients that account for differences in how these patients clear bisphosphonate s from their systems. Determining such genetic differences provides for improved monitoring of the drugs used to treat BONJ, improved prevention of BONJ, and optimized treatment for patients having BONJ or predisposed to BOND.
FIELD: medicine, stomatology. SUBSTANCE: invention relates to nonpharmacological medicinal preparations for parodontitis treatment. Medicinal mixture has the following components, wt.-%: aloe sap 5-20; natural honey 20-40; lemon juice 5-20, and milled walnut kernels 25-40. Biostimulating aloe sap is obtained by leaves pressing after their preliminary exposition in cooling, in dark for 12-15 days. Mixture is used for treatment of inflammatory processes associated with avitaminosis and dystrophic processes damaging tissues. EFFECT: enhanced effectiveness of mixture. 3 cl
<P>PROBLEM TO BE SOLVED: To provide a technique to prevent preinstallation of an image reconstructing and processing software which is necessary for reconstructing and processing an image on the basis of data acquired from a server.  <P>SOLUTION: An interactive method is provided which allows a user to acquire diagnostic image data from a server having access to stored data via a network with a restricted communication bandwidth and to carry out on-line processing of the diagnostic image data. The method comprises the step of connecting a user's computer and the server via a communication network, the step of requesting specific image data, the step of transmitting the requested image data to a user, the step of reconstructing an image on the basis of the image data, and the step of carrying out image processing of the image on the user's computer. During the connecting step, an industry standard browser on the user's computer is used. In the method, an image having diagnostic image quality is reconstructed and is subjected to image processing without involvement of the user by using an image reconstructing and processing software received from the server.  <P>COPYRIGHT: (C)2008,JPO&INPIT
This cohort will comprise participants with PD-L1 high, cancer immunotherapy (CIT) naïve first line NSCLC. The starting dose of lomvastomig for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
Among all non-communicable diseases, Cardiovascular Diseases (CVDs) stand as the leading global cause of mortality. Within this spectrum, Myocardial Infarction (MI) strikingly accounts for over 15 % of all deaths. The intricate web of risk factors for MI, comprising family history, tobacco use, oral health, hypertension, nutritional pattern, and microbial infections, is firmly influenced by the human gut and oral microbiota, their diversity, richness, and dysbiosis, along with their respective metabolites. Host genetic factors, especially allelic variations in signaling and inflammatory markers, greatly affect the progression or severity of the disease. Despite the established significance of the human microbiome-nutrient-metabolite interplay in associations with CVDs, the unexplored terrain of the gut-heart-oral axis has risen as a critical knowledge gap. Moreover, the pivotal role of the microbiome and the complex interplay with host genetics, compounded by age-related changes, emerges as an area of vital importance in the development of MI. In addition, a distinctive disease susceptibility and severity influenced by gender-based or ancestral differences, adds a crucial insights to the association with increased mortality. Here, we aimed to provide an overview on interactions of microbiome (oral and gut) with major risk factors (tobacco use, alcohol consumption, diet, hypertension host genetics, gender, and aging) in the development of MI and therapeutic regulation.
Aging or damaged skin is treated by irradiating affected skin areas with an effective amount of blue and/or violet visible light having a wavelength of about 400 nm to about 500 nm. The light may be sunlight or artificial light, coherent or noncoherent, pulsed or continuous, of high or low energy, exposed generally or directed to target areas, or any combination of these. A variety of irradiation methods may be employed. In one embodiment, filtered sun or artificial light is used. This can be widely exposed to skin areas, or directed to discrete skin regions, particularly to areas especially susceptible to aging, e.g., the backs of hands and the periorbital and perioral areas of the face. In an alternate embodiment, light-emitting diodes are applied directly to discrete skin areas as needed as patches or thin sheets such as pliable masks. Green light (about 500 to about 590 nm) may be used as adjunct therapy with blue/violet light in some embodiments. Compositions containing compounds that enhance light penetration of the stratum corneum such as α-hydroxy acids (e.g., glycolic acid) and/or filter light may be applied to the skin prior to or during phototreatment.
The invention belongs to the field of development of canine distemper virus protein vaccines, and discloses a nucleotide sequence (delta H), wherein the nucleotide sequence is SEQ ID NO. 1. SEQ ID NO.1 is linked to a corresponding vector gene, for example, the ferritin gene (. DELTA.F), forming gene fragment (. DELTA.H-F) having the nucleotide sequence of SEQ ID NO. 2. After being recombined with a prokaryotic protein expression vector system, the SEQ ID NO.2 expresses soluble rH-F nano particles and can be applied to vaccines for preventing canine distemper virus.
AIMS: The anthracycline family of anticancer agents such as doxorubicin (DOX) can induce apoptotic death of cardiomyocytes and cause cardiotoxicity. We previously reported that DOX-induced apoptosis is accompanied by cardiomyocyte cell cycle re-entry. Cell cycle progression requires cyclin-dependent kinase 7 (CDK7)-mediated activation of downstream cell cycle CDKs. This study aims to determine whether CDK7 can be targeted for cardioprotection during anthracycline chemotherapy.
METHODS AND RESULTS: DOX exposure induced CDK7 activation in mouse heart and isolated cardiomyocytes. Cardiac-specific ablation of Cdk7 attenuated DOX-induced cardiac dysfunction and fibrosis. Treatment with the covalent CDK7 inhibitor THZ1 also protected against DOX-induced cardiomyopathy and apoptosis. DOX treatment induced activation of the proapoptotic CDK2-FOXO1-Bim axis in a CDK7-dependent manner. In response to DOX, endogenous CDK7 directly bound and phosphorylated CDK2 at Thr160 in cardiomyocytes, leading to full CDK2 kinase activation. Importantly, inhibition of CDK7 further suppressed tumour growth when used in combination with DOX in an immunocompetent mouse model of breast cancer.
CONCLUSION: Activation of CDK7 is necessary for DOX-induced cardiomyocyte apoptosis and cardiomyopathy. Our findings uncover a novel proapoptotic role for CDK7 in cardiomyocytes. Moreover, this study suggests that inhibition of CDK7 attenuates DOX-induced cardiotoxicity but augments the anticancer efficacy of DOX. Therefore, combined administration of CDK7 inhibitor and DOX may exhibit diminished cardiotoxicity but superior anticancer activity.
- 105 The disclosure provides methods for treating a subject having a type I IFN-mediated disease or disorder comprising administration of a fixed dose of an anti-interferon alpha receptor antibody. The disclosure also provides methods for suppressing a type I interferon (IFN) gene signature (GS) in a subject. In addition, the disclosure provides methods of prognosing or monitoring disease progression in a subject having a type I IFN-mediated disease or disorder, methods of predicting a dosage regimen, methods of identifying a candidate therapeutic agent, methods of identifying a patient as a candidate for a therapeutic agent, and methods of designing a personalized therapy. Atty. Dkt. No. 2943.0350000
Participants will enroll in heart disease prevention group sessions focusing on physical activity, diet, weight, and stress management. Each group will have 16 to 20 participants who will attend 16 weekly, 90 minute group education sessions at Metropolitan Asian Family Services or Skokie Health Department. During each session, participants will watch videos on the day's topic followed by discussion, activities, and assistance in setting realistic goals with attention to physical activity, diet, weight, and stress management.
BACKGROUND: Meningioma, the most prevalent intracranial tumor, possesses a significant propensity for malignant transformation. Circular RNAs (circ-RNAs), a class of non-coding RNAs, have emerged as crucial players in tumorigenesis. This study explores the functional relevance of hsa_circ_0004872, a specific circ-RNA, in the context of meningioma.
METHODS: Molecular structure and stability of hsa_circ_0004872 were elucidated through PCR identification. Meningioma cell proliferation and apoptosis were assessed using the CCK-8 assay and flow cytometry, respectively. Gene and protein expression were analyzed via qRT-PCR and western blot. Molecular interactions were confirmed through dual-luciferase reporter gene and RIP assays.
RESULTS: Hsa_circ_0004872, derived from exons 2 to 4 of the host gene MAPK1, demonstrated enhanced stability compared to its host MAPK1. Clinical data described that hsa_circ_0004872 was reduced in meningioma tissues and cell lines, and negatively correlated to poor survival rate of meningioma patients. Overexpression of hsa_circ_0004872 exhibited inhibitory effects on cell proliferation and promotion of apoptosis in vitro. Subsequent investigations unveiled a direct interaction between hsa_circ_0004872 and miR-190a-3p, leading to the activation of the PI3K/AKT signaling pathway through targeting PTEN. Notably, miR-190a-3p silence accelerated the apoptosis and proliferation inhibition of meningioma cells by inactivating PTEN/PI3K/AKT signaling, while miR-190a-3p overexpression showed an opposite effect, which greatly reversed the anti-tumor effects of hsa_circ_0004872 overexpression.
CONCLUSION: In summary, our findings highlighted the intricate role of hsa_circ_0004872 in meningioma, shedding light on the regulatory mechanisms involving circ-RNAs in tumor progression. This positions hsa_circ_0004872 as a potential key regulatory factor in meningioma with implications for future therapeutic interventions.
According to some implementations of the present disclosure, a system for identifying individuals at risk for PDAC includes a CT scanner, a memory, and a control system. The CT scanner is configured to generate CT image data associated with a pancreas of a patient. The memory stores machine-readable instructions. The control system includes one or more processors configured to execute the machine-readable instructions. The CT image data associated with the pancreas of the patient is received. The received CT image data is processed to output a set of CT image features. The set of CT image features is received as an input to a machine learning PDAC prediction algorithm. An indication of whether the patient is at high risk for PDAC is determined as an output of the machine learning PDAC prediction algorithm.
<P>PROBLEM TO BE SOLVED: To obtain a cosmetic that improves a defect that a colored cosmetic in a transparent container has an excellent appearance but poor light resistance and fading and change of color occur by light.  <P>SOLUTION: The cosmetic comprises a tar coloring matter, an organic ultraviolet light absorber and condensation type persimmon tannin. The amount of the organic ultraviolet light absorber mixed is preferably 0.001-0.5 wt.%, more preferably 0.01-0.1 wt.%. The amount of the condensation type persimmon tannin is preferably 0.0005-0.25 wt.%, more preferably 0.005-0.05 wt.%. The cosmetic has excellent light resistance and a vivid color.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The present invention provides a skin care composition produced by mixing and heating one or more of Angelica gigas, lemons, and onions with a salmon extract extracted from salmon by smoking the salmon. An effective microorganism (EM) fermented liquid and sodium hydroxide are mixed and agitated with the salmon extract so that a solid soap is produced. The soap is re-melted and aged. One or more of Angelica gigas, licorice, jasmine, peppermint, green tea, guava, lemons, citron, tangerines, and oranges are added and re-heated in the aged liquid, and the re-heated mixture is filtered, so that only a liquid is collected and left for 10 to 30 hours and a washing liquid is provided. A skin care product and a washing agent of the present invention are coated on atopic, eczematous, athlete′s foot, and insect bite regions to alleviate itching and have moisturizing and whitening effects. The washing agent has an excellent effect in washing the skin, scalp, hair, dishes, kitchen, and bathroom.
Described are synthetic compounds having anti-inflammatory properties and optionally analgesic properties. These compounds are derivatives of FDA-approved anti-inflammatory, such as ibuprofen and indomethacin, and can be formed using reactions under microwave irradiation. Generally, the compounds contains a moiety of the parent drug, a triazolyl heterocycle, and a substituted or unsubstituted aryl group. In some forms, the compounds show anti-inflammatory properties and optionally analgesic properties with similar or higher efficiencies compared with their respective parent drugs, with additional advantages including no or reduced adverse effects (e.g., without ulcerogenic liability in the gastric) and/or selective inhibition of COX-2 over COX-1. Pharmaceutical compositions suitable for the delivery of the compounds to a subject in need thereof are disclosed. The pharmaceutical formulation can be administered by oral administration, parenteral administration, inhalation, mucosal administration, or a combination thereof. Methods for preventing or treating an inflammatory disease or disorder in a subject are also disclosed.
Patients will receive two treatment sequences. Participants will complete two overnight sleep studies and cross-over with 1-week wash-out period The participants will receive Lemborexant 5 mg per day 5 minutes before lights-out for one dose for the first overnight sleep test of the experiment. After 1 week wash-out period, the participants will cross to the placebo arm and receive placebo 5 minutes before lights-out for one dose for the second overnight sleep test of the experiment.
The invention relates to a traditional Chinese patent medicine for remedying the salpingitis, which adopts more than ten kinds of traditional Chinese herbal medicines of a myrrh, a lychee seed, droppings of flying squirrel, a dried cattail pollen etc. as the raw materials. The traditional Chinese patent medicine has the efficacies of warming channel for dispelling cold and promoting blood circulation to stop pain. The invention is developed and manufactured based on the traditional Chinese medicinal differentiation treatment and is combined with the latest modern scientific research achievement. The purpose of the invention is to provide a traditional Chinese patent medicine for remedying the salpingitis. The invention has the characteristics of accurate curative effect, being safe and convenient, no toxic and side effect and low price.
Dry mouth is a common complaint of radiotherapy for cancer of the head and neck region. It is a distressing often persistent condition which can lead to longlasting oral discomfort, dental infections, diminished quality of life, social isolation and loneliness. Unfortunately, current therapies of dry mouth are often unsatisfactory, expensive and may result in adverse effects. A novel intraoral electronic device has recently been developed to treat dry mouth. The device, acting as a "salivary pacemaker", harmlessly stimulates nerves of the salivary glands and does not cause adverse side effects. The aim of this proposal is to assess the longterm effects of such a device in this population, which have yet to be investigated, to demonstrate whether its daily application is an effective method of lessening dry mouth and improving life quality. 84 individuals will be enrolled in the study to use the device for 12 months, after receiving appropriate instructions. 42 participants (out of 84) will act as controls as they will receive a sham device that will not deliver electric stimuli but only tactile stimulation (like using a chewing gum). All participants will be allowed to continue using their routine local therapy for dry mouth (e.g. artificial saliva) during the study. Each participant will keep a diary relevant to the frequency of use and potential changes in dry mouth sensation. Participants will also be asked to attend hospital appointments to measure changes in saliva production and complete questionnaires on their dry mouth and quality of life. The device has the potential to radically change current clinical practice. If the trial is successful, the use of the device will provide patients having radiation-induced dry mouth with a safe and drug-free therapeutic modality.